Disposition of 2900 shares by Ilya Goldshleger of Rxsight at 54.9616 subject to Rule 16b-3
| RXST Stock | USD 7.92 0.12 1.54% |
Slightly above 52% of Rxsight's investor base is interested to short. The analysis of overall sentiment of trading Rxsight stock suggests that many investors are impartial at this time. Rxsight's investing sentiment can be driven by a variety of factors including economic data, Rxsight's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Rxsight Officer See Remarks. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Rxsight Fundamental Analysis
We analyze Rxsight's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rxsight using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rxsight based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Rxsight is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Rxsight Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rxsight stock to make a market-neutral strategy. Peer analysis of Rxsight could also be used in its relative valuation, which is a method of valuing Rxsight by comparing valuation metrics with similar companies.
Peers
Rxsight Related Equities
| SGHT | Sight Sciences | 6.12 | ||||
| CTKB | Cytek Biosciences | 5.49 | ||||
| RPID | Rapid Micro | 5.44 | ||||
| TMCI | Treace Medical | 5.06 | ||||
| SIBN | Si Bone | 2.93 | ||||
| TCMD | Tactile Systems | 2.49 | ||||
| LUNG | Pulmonx Corp | 2.48 | ||||
| IMRX | Immuneering Corp | 1.78 |
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.